MDT-AP-2385
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 72.24
- os_event
- true
- age_years
- 9.92
- sex
- F
- new_clusters
- S2
- umap1_2d
- -1.75424025
- umap2_2d
- -10.58641251
- umap1_3d
- -2.17783898
- umap2_3d
- -1.299941724
- umap3_3d
- 5.080370213
- dataset
- Med-Taylor
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0712 | Med | Medulloblastoma | 0.757 |
| 2 | MDT-AP-0565 | Med | Medulloblastoma | 0.720 |
| 3 | MNG1120 | — | — | 0.692 |
| 4 | MDT-AP-0386 | Med | Medulloblastoma | 0.680 |
| 5 | MDT-AP-2168 | Med | Medulloblastoma | 0.672 |
| 6 | SRR5903558 | — | cohortMD2 | 0.671 |
| 7 | MDT-AP-0809 | Med | Medulloblastoma | 0.664 |
| 8 | MNG208 | — | — | 0.663 |
| 9 | MDT-AP-0725 | Med | Medulloblastoma | 0.658 |
| 10 | MDT-AP-0732 | Med | Medulloblastoma | 0.648 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.230 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.110 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.080 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |